$116 Million is the total value of Context Capital Management, LLC's 48 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 112.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Buy | AMAG PHARMACEUTICALS INCnote 3.250% 6/0 | $9,006,000 | +15.4% | 8,800,000 | +16.6% | 7.74% | +36.7% | |
Buy | THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $5,466,000 | +53.2% | 5,500,000 | +57.1% | 4.70% | +81.5% | |
Buy | VECTOR GROUP LTDfrnt | $5,281,000 | +220.3% | 5,000,000 | +233.3% | 4.54% | +279.4% | |
New | MICROCHIP TECHNOLOGY INCnote 2.250% 2/1 | $5,247,000 | – | 4,400,000 | +100.0% | 4.51% | – | |
Buy | DEPOMED INCnote 2.500% 9/0 | $4,514,000 | +22.3% | 5,500,000 | +22.2% | 3.88% | +44.9% | |
Buy | MEDICINES COnote 2.750% 7/1 | $3,031,000 | +530.1% | 3,000,000 | +500.0% | 2.61% | +646.7% | |
Buy | TESLA INCnote 2.375% 3/1 | $2,432,000 | +365.0% | 2,000,000 | +300.0% | 2.09% | +450.3% | |
LQD | Buy | ISHARES TRiboxx inv cp etf | $2,406,000 | +46.4% | 21,000 | +50.0% | 2.07% | +73.6% |
New | DERMIRA INCnote 3.000% 5/1 | $2,085,000 | – | 2,525,000 | +100.0% | 1.79% | – | |
LFACU | New | LF CAP ACQUISITION CORPunit 06/19/2025 | $2,016,000 | – | 200,190 | +100.0% | 1.73% | – |
New | CHART INDS INCnote 2.000% 8/0 | $1,898,000 | – | 1,874,000 | +100.0% | 1.63% | – | |
MUDSU | Buy | MUDRICK CAP ACQUISITION CORPunit 02/01/2023 | $1,456,000 | +42.5% | 140,000 | +40.0% | 1.25% | +68.7% |
TMCXU | New | TRINITY MERGER CORPunit 05/11/2025 | $1,226,000 | – | 121,868 | +100.0% | 1.05% | – |
New | ROVI CORPnote 0.500% 3/0 | $954,000 | – | 1,000,000 | +100.0% | 0.82% | – | |
New | CALAMP CORPnote 1.625% 5/1 | $954,000 | – | 893,000 | +100.0% | 0.82% | – | |
New | CLOVIS ONCOLOGY INCnote 1.250% 5/0 | $924,000 | – | 1,000,000 | +100.0% | 0.79% | – | |
New | INTERCEPT PHARMACEUTICALS INnote 3.250% 7/0 | $484,000 | – | 5,500,000 | +100.0% | 0.42% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
THERAVANCE BIOPHARMA INC | 23 | Q2 2022 | 4.7% |
ENCORE CAPITAL GROUP INC | 19 | Q2 2019 | 6.2% |
INTERCEPT PHARMACEUTICALS IN | 18 | Q4 2022 | 6.2% |
INFINERA CORPORATION | 18 | Q1 2023 | 3.6% |
TESLA MTRS INC | 16 | Q1 2019 | 4.9% |
DISH NETWORK CORPORATION | 16 | Q3 2023 | 3.3% |
ENDOLOGIX INC | 15 | Q2 2019 | 11.6% |
OMEROS CORP | 15 | Q3 2023 | 3.1% |
VANGUARD TOTAL STOCK MKT ETF | 15 | Q1 2020 | 3.9% |
AMAG PHARMACEUTICALS INC | 14 | Q3 2020 | 7.7% |
View Context Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ELECTRO ENERGY INC | February 17, 2009 | 326,124 | 4.9% |
IRONCLAD PERFORMANCE WEAR CORPSold out | February 17, 2009 | 0 | 0.0% |
Jazz Technologies, Inc.Sold out | February 17, 2009 | 0 | 0.0% |
VELOCITY EXPRESS CORP | February 17, 2009 | 190,104 | 5.3% |
ATS CORP | June 17, 2008 | 723,073 | 3.6% |
Ascend Acquisition Corp.Sold out | June 16, 2008 | 0 | 0.0% |
HIGHBURY FINANCIAL INCSold out | June 16, 2008 | 0 | 0.0% |
PRIMUS TELECOMMUNICATIONS GROUP INCSold out | June 16, 2008 | 0 | 0.0% |
Good Harbor Partners Acquisition CorpSold out | February 13, 2008 | 0 | 0.0% |
InfuSystem Holdings, Inc | February 13, 2008 | 152,350 | 0.8% |
View Context Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-02 |
SCHEDULE 13G | 2024-03-20 |
13F-HR/A | 2024-02-16 |
13F-HR | 2024-02-09 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-10 |
13F-HR | 2023-05-08 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-07 |
13F-HR | 2022-08-03 |
View Context Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.